scholarly journals Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy?

2021 ◽  
Vol 11 ◽  
Author(s):  
Wei Xu ◽  
Wentao Liu ◽  
Lingquan Wang ◽  
Changyu He ◽  
Sheng Lu ◽  
...  

BackgroundFor gastric cancer (GC) with extensive lymph node metastasis (bulky N2 and/or para-aortic lymph node metastases), there is no standard therapy worldwide. In Japan, preoperative chemotherapy (PCT) followed by D2 gastrectomy plus para-aortic lymph node dissection (PAND) is considered the standard treatment for these patients. However, in China, the standard operation for GC patients with only bulky N2 metastases was D2 gastrectomy. Besides, after PCT, whether doing PAND improves survival or not is debatable for GC patients with para-aortic lymph node (PAN) metastases. Therefore, we conducted this study to investigate whether D2 lymphadenectomy alone is suitable for these patients after PCT.MethodsWe retrospectively collected data on patients from our electronic medical record system. GC patients with bulky N2 and/or PAN metastases who underwent D2 lymphadenectomy alone after PCT were enrolled. The survival outcomes and chemotherapy responses were analyzed and compared with the results of the JCOG0405 study.ResultsFrom May 2009 to December 2017, a total of 83 patients met all eligibility criteria and were enrolled. The median survival duration for all patients was 40.0 months. The 3-year and 5-year OS rates for all patients were 50.3% and 45.6%, respectively. For patients with only bulky N2 metastasis, the 3-year and 5-year OS rates were 77.1% and 71.6%, respectively, which were similar to the results of the JCOG0405 study (82.7% and 73.4%). For patients with only PAN metastases, the 3-year and 5-year OS rates were 50.0% and 50.0%, respectively, which seemed to be lower than those of the JCOG0405 study (64.3% and 57.1%). For patients with bulky N2 and PAN metastases, the 3-year and 5-year OS rates were 7.4% and 0.0%, respectively, which were lower than those of the JCOG0405 study (20.0% and 20.0%).ConclusionThe results of our study suggest that D2 lymphadenectomy alone is suitable for GC patients with only bulky N2 metastasis after PCT. However, D2 lymphadenectomy alone perhaps is not suitable for patients with bulky N2 and PAN metastases after PCT.

2014 ◽  
Vol 74 (2) ◽  
pp. 433-434 ◽  
Author(s):  
Daniele Marrelli ◽  
Maria Antonietta Mazzei ◽  
Franco Roviello

2011 ◽  
Vol 18 (8) ◽  
pp. 2265-2272 ◽  
Author(s):  
Daniele Marrelli ◽  
Maria Antonietta Mazzei ◽  
Corrado Pedrazzani ◽  
Marianna Di Martino ◽  
Carla Vindigni ◽  
...  

2017 ◽  
Vol 50 (5) ◽  
pp. 364-371
Author(s):  
Takanori Jinno ◽  
Yasuhiro Kurumiya ◽  
Ei Sekoguchi ◽  
Satoshi Kobayashi ◽  
Kiyotaka Kawai ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e14713-e14713
Author(s):  
Antonio CALDEIRA Fradique

e14713 Background: The Cerb-B2/HER2 marker, is a glycoprotein encoded by the ERBB2 oncogene, belongs to the family of epidermal growth factor receptors (EGFR), which has based its application on tests of new therapeutic modalities (target therapy). Apart from this interest has been invoked its value as a marker of tumor aggressiveness, due to his role as a regulator of cell proliferation and migration and consequent invasiveness and metastization. However, the results as to the meaning prognosis of this molecular marker are controversial and with variations depending on the geographical zone. Results: From a total of 50 pts. with advanced resectable gastric cancer that underwent surgery with D2 lymphadenectomy, 38 pts. had a total gastrectomy, and 12 pts. had subtotal gastrectomy. A mean of 35.7 lymph nodes/pt were resected at surgery. In 68% of pts. positive lymph node metastases were present. Tumor HER2-neu overexpression was observed in 16 pts (32%), several other parameters of tumor aggressiveness were also present, without any statistical significance or relevance. Methods: To determine if the Cerb-B2 played a prognostic role in gastric cancer, a total of 50 pts. with advanced resectable gastric cancer, were submitted to gastrectomy with D2 lymphadenectomy. In all cases assessment for tumor HER2-neu overexpression was performed using immunohistochemistry (IHC). FISH was used as a confirmation method in tumors with 2+ expression by IHC. A correlation was made between the tumor HER2-neu expression and the following parameters: tumor location, size, histological type, depth of invasion, lymph node metastases and clinical staging. Results: From a total of 50 pts. with advanced resectable gastric cancer that underwent surgery with D2 lymphadenectomy, 38 pts. had a total gastrectomy, and 12 pts. had subtotal gastrectomy. A mean of 35.7 lymph nodes/pt were resected at surgery. In 68% of pts. positive lymph node metastases were present.Tumor HER2-neu overexpression was observed in 16 pts (32%), several other parameters of tumor aggressiveness were also present, without any statistical significance or relevance. Conclusions: The determination of Cerb-B2 / HER2 expression has not shown prognostic significance in this study.


1999 ◽  
Vol 2 (4) ◽  
pp. 235-239 ◽  
Author(s):  
Takao Inada ◽  
Yoshiro Ogata ◽  
Iwao Ozawa ◽  
Moriaki Tomikawa ◽  
Seichiro Yamamoto ◽  
...  

1976 ◽  
Vol 9 (2) ◽  
pp. 112-116 ◽  
Author(s):  
Ichiro OHASHI ◽  
Kunio TAKAGI ◽  
Toshiro KONISHI ◽  
Shiro IZUMOI ◽  
Atsuo FUKAMI ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document